Identification of Dominant Negative Mutants of Rheb GTPase and Their Use to Implicate the Involvement of Human Rheb in the Activation of p70S6K
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Rheb GTPases represent a unique family of the Ras superfamily of G-proteins. Studies on Rheb in Schizosaccharomyces pombe and Drosophila have shown that this small GTPase is essential and is involved in cell growth and cell cycle progression. The Drosophila studies also raised the possibility that Rheb is involved in the TOR/S6K signaling pathway. In this paper, we first report identification of dominant negative mutants of S. pombe Rheb (SpRheb). Screens of a randomly mutagenized SpRheb library yielded a mutant, SpRhebD60V, whose expression in S. pombe results in growth inhibition, G1 arrest, and induction of fnx1+, a gene whose expression is induced by the disruption of Rheb. Alteration of the Asp-60 residue to all possible amino acids by site-directed mutagenesis led to the identification of two particularly strong dominant negative mutants, D60I and D60K. Characterization of these dominant negative mutant proteins revealed that D60V and D60I exhibit preferential binding of GDP, while D60K lost the ability to bind both GTP and GDP. A possible use of the dominant negative mutants in the study of mammalian Rheb was explored by introducing dominant negative mutations into human Rheb. We show that transient expression of the wild type Rheb1 or Rheb2 causes activation of p70S6K, while expression of Rheb1D60K mutant results in inhibition of basal level activity of p70S6K. In addition, Rheb1D60K and Rheb1D60V mutants blocked nutrient- or serum-induced activation of p70S6K. This provides critical evidence that Rheb plays a role in the mTOR/S6K pathway in mammalian cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
[56] Molecular genetic analysis of fission yeast Schizosaccharomyces pombe
Moreno, S., Klar, A., & Nurse, P. (1991) · Methods in Enzymology · doi:10.1016/0076-6879(91)94059-l · Cited by 3,620
The GTPase superfamily: conserved structure and molecular mechanism
Bourne, H. R., Sanders, D. A., & McCormick, F. (1991) · Nature · doi:10.1038/349117a0 · Cited by 3,392
A mammalian protein targeted by G1-arresting rapamycin–receptor complex
Brown, E. J., Albers, M. W., Bum Shin, T., ichikawa, K., Keith, C. T., Lane, W. S., & Schreiber, S. L. (1994) · Nature · doi:10.1038/369756a0 · Cited by 2,053
The structural basis of the activation of Ras by Sos
Boriack-Sjodin, P. A., Margarit, S. M., Bar-Sagi, D., & Kuriyan, J. (1998) · Nature · doi:10.1038/28548 · Cited by 799
The Ras-related Protein Rheb Is Farnesylated and Antagonizes Ras Signaling and Transformation
Clark, G. J., Kinch, M. S., Rogers-Graham, K., Sebti, S. M., Hamilton, A. D., & Der, C. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.16.10608 · Cited by 177
Panepinto, J. C., Oliver, B. G., Fortwendel, J. R., Smith, D. L. H., Askew, D. S., & Rhodes, J. C. (2003) · Infection and Immunity · doi:10.1128/iai.71.5.2819-2826.2003 · Cited by 72
Cited by
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
The TSC1–TSC2 complex: a molecular switchboard controlling cell growth
Huang, J., & Manning, B. D. (2008) · Biochemical Journal · doi:10.1042/bj20080281 · Cited by 1,237
Rheb Binds and Regulates the mTOR Kinase
Long, X., Lin, Y., Ortiz-Vega, S., Yonezawa, K., & Avruch, J. (2005) · Current Biology · doi:10.1016/j.cub.2005.02.053 · Cited by 1,005
The molecular machinery of autophagy: unanswered questions
Klionsky, D. J. (2005) · Journal of Cell Science · doi:10.1242/jcs.01620 · Cited by 933
Regulation of mTORC1 by PI3K signaling
Dibble, C. C., & Cantley, L. C. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.06.002 · Cited by 836
AMPK and mTOR in Cellular Energy Homeostasis and Drug Targets
Inoki, K., Kim, J., & Guan, K.-L. (2012) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134537 · Cited by 791
Targeting protein prenylation for cancer therapy
Berndt, N., Hamilton, A. D., & Sebti, S. M. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3151 · Cited by 614
Regulation and role of autophagy in mammalian cells
Meijer, A. J., & Codogno, P. (2004) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.02.002 · Cited by 615
Land, S. C., & Tee, A. R. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m611782200 · Cited by 507
Konstantinopoulos, P. A., Karamouzis, M. V., & Papavassiliou, A. G. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2221 · Cited by 451
TSC2: filling the GAP in the mTOR signaling pathway
Li, Y. (2004) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2003.11.007 · Cited by 419
Rheb Activates mTOR by Antagonizing Its Endogenous Inhibitor, FKBP38
Bai, X., Ma, D., Liu, A., Shen, X., Wang, Q. J., Liu, Y., & Jiang, Y. (2007) · Science · doi:10.1126/science.1147379 · Cited by 382
Smith, E. M., Finn, S. G., Tee, A. R., Browne, G. J., & Proud, C. G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414499200 · Cited by 355
Signaling by Target of Rapamycin Proteins in Cell Growth Control
Inoki, K., Ouyang, H., Li, Y., & Guan, K.-L. (2005) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.69.1.79-100.2005 · Cited by 330
Therapeutic Strategies for Targeting Ras Proteins
Gysin, S., Salt, M., Young, A., & McCormick, F. (2011) · Genes & Cancer · doi:10.1177/1947601911412376 · Cited by 323
Thematic review series: Lipid Posttranslational Modifications. Farnesyl transferase inhibitors
Basso, A. D., Kirschmeier, P., & Bishop, W. R. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r500012-jlr200 · Cited by 297
Wang, C., Mao, X., Wang, L., Liu, M., Wetzel, M. D., Guan, K.-L., Dong, L. Q., & Liu, F. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700098200 · Cited by 210
Sato, T., Nakashima, A., Guo, L., & Tamanoi, F. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m809207200 · Cited by 196
Self-citationSchäffner, I., Minakaki, G., Khan, M. A., Balta, E.-A., Schlötzer-Schrehardt, U., Schwarz, T. J., Beckervordersandforth, R., Winner, B., Webb, A. E., DePinho, R. A., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.08.017 · Cited by 145
“To this end, we retrovirally overexpressed a dominant-negative mutant of the mTOR activator Rheb GTPase, Rheb, which powerfully inhibits mTOR activity (Tabancay et al., 2003).”
A small molecule inhibitor of Rheb selectively targets mTORC1 signaling
Mahoney, S. J., Narayan, S., Molz, L., Berstler, L. A., Kang, S. A., Vlasuk, G. P., & Saiah, E. (2018) · Nature Communications · doi:10.1038/s41467-018-03035-z · Cited by 88
Taneike, M., Nishida, K., Omiya, S., Zarrinpashneh, E., Misaka, T., Kitazume-Taneike, R., Austin, R., Takaoka, M., Yamaguchi, O., Gambello, M. J., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0152628 · Cited by 57
“The TSC1/2 complex is a GTPase-activating protein that catalyses the conversion of Rheb-GTP to Rheb-GDP [11] and inactivates Rheb, resulting in inhibition of mTORC1 signaling [12, 13].”
BackgroundProbing the GTPase cycle with real-time NMR: GAP and GEF activities in cell extracts
Marshall, C. B., Meiri, D., Smith, M. J., Mazhab-Jafari, M. T., Gasmi-Seabrook, G. M. C., Rottapel, R., Stambolic, V., & Ikura, M. (2012) · Methods · doi:10.1016/j.ymeth.2012.06.014 · Cited by 46
Rheb G-Proteins and the Activation of mTORC1
(2010) · The Enzymes · doi:10.1016/s1874-6047(10)27003-8 · Cited by 41
“While they exhibit the ability to downregulate the mTOR signaling [33], expression of these mutants was low limiting their use for the analysis of the mTOR signaling.”
BackgroundSelf-citation
Metadata
- Authors
- Tabancay, A. P., Gau, C.-L., Machado, I. M. P., Uhlmann, E. J., Gutmann, D. H., Guo, L., & Tamanoi, F.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2003-10
- Volume
- 278
- Issue
- 41
- Pages
- 39921-39930
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2075092037
- Cited by
- 107
- References
- 6
- FWCI
- 3.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.